Literature DB >> 29128754

Development and characterization of a human monoclonal antibody targeting the N-terminal region of hepatitis C virus envelope glycoprotein E1.

Ahmed Atef Mesalam1, Isabelle Desombere2, Ali Farhoudi3, Freya Van Houtte4, Lieven Verhoye5, Jonathan Ball6, Jean Dubuisson7, Steven K H Foung8, Arvind H Patel9, Mats A A Persson10, Geert Leroux-Roels11, Philip Meuleman12.   

Abstract

Monoclonal antibodies (mAbs) targeting the hepatitis C virus (HCV) envelope have been raised mainly against envelope protein 2 (E2), while the antigenic epitopes of envelope protein 1 (E1) are not fully identified. Here we describe the detailed characterization of a human mAb, designated A6, generated from an HCV genotype 1b infected patient. ELISA results showed reactivity of mAb A6 to full-length HCV E1E2 of genotypes 1a, 1b and 2a. Epitope mapping identified a region spanning amino acids 230-239 within the N-terminal region of E1 as critical for binding. Antibody binding to this epitope was not conformation dependent. Neutralization assays showed that mAb A6 lacks neutralizing capacity and does not interfere with the activity of known neutralizing antibodies. In summary, mAb A6 is an important tool to study the structure and function of E1 within the viral envelope, a crucial step in the development of an effective prophylactic HCV vaccine.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Antibody; Entry; Envelope protein; Hepatitis C virus; Vaccine

Mesh:

Substances:

Year:  2017        PMID: 29128754      PMCID: PMC5784761          DOI: 10.1016/j.virol.2017.10.019

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  61 in total

1.  Non-neutralizing epitopes induce robust hepatitis C virus (HCV)-specific antibody-dependent CD56+ natural killer cell responses in chronic HCV-infected patients.

Authors:  L Long; M Jia; X Fan; H Liang; J Wang; L Zhu; Z Xie; T Shen
Journal:  Clin Exp Immunol       Date:  2017-04-07       Impact factor: 4.330

2.  Human B cell growth and differentiation in the spleen of immunodeficient mice.

Authors:  S Depraetere; L Verhoye; G Leclercq; G Leroux-Roels
Journal:  J Immunol       Date:  2001-03-01       Impact factor: 5.422

3.  Characterization of host-range and cell entry properties of the major genotypes and subtypes of hepatitis C virus.

Authors:  Dimitri Lavillette; Alexander W Tarr; Cécile Voisset; Peggy Donot; Birke Bartosch; Christine Bain; Arvind H Patel; Jean Dubuisson; Jonathan K Ball; François-Loïc Cosset
Journal:  Hepatology       Date:  2005-02       Impact factor: 17.425

Review 4.  Virology and cell biology of the hepatitis C virus life cycle: an update.

Authors:  Jean Dubuisson; François-Loïc Cosset
Journal:  J Hepatol       Date:  2014-11-03       Impact factor: 25.083

5.  Monoclonal antibody AP33 defines a broadly neutralizing epitope on the hepatitis C virus E2 envelope glycoprotein.

Authors:  Ania Owsianka; Alexander W Tarr; Vicky S Juttla; Dimitri Lavillette; Birke Bartosch; François-Loïc Cosset; Jonathan K Ball; Arvind H Patel
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

6.  The disulfide bonds in glycoprotein E2 of hepatitis C virus reveal the tertiary organization of the molecule.

Authors:  Thomas Krey; Jacques d'Alayer; Carlos M Kikuti; Aure Saulnier; Laurence Damier-Piolle; Isabelle Petitpas; Daniel X Johansson; Rajiv G Tawar; Bruno Baron; Bruno Robert; Patrick England; Mats A A Persson; Annette Martin; Félix A Rey
Journal:  PLoS Pathog       Date:  2010-02-19       Impact factor: 6.823

7.  Viral entry and escape from antibody-mediated neutralization influence hepatitis C virus reinfection in liver transplantation.

Authors:  Samira Fafi-Kremer; Isabel Fofana; Eric Soulier; Patric Carolla; Philip Meuleman; Geert Leroux-Roels; Arvind H Patel; François-Loïc Cosset; Patrick Pessaux; Michel Doffoël; Philippe Wolf; Françoise Stoll-Keller; Thomas F Baumert
Journal:  J Exp Med       Date:  2010-08-16       Impact factor: 14.307

8.  Glycan shifting on hepatitis C virus (HCV) E2 glycoprotein is a mechanism for escape from broadly neutralizing antibodies.

Authors:  Homer Pantua; Jingyu Diao; Mark Ultsch; Meredith Hazen; Mary Mathieu; Krista McCutcheon; Kentaro Takeda; Shailesh Date; Tommy K Cheung; Qui Phung; Phil Hass; David Arnott; Jo-Anne Hongo; David J Matthews; Alex Brown; Arvind H Patel; Robert F Kelley; Charles Eigenbrot; Sharookh B Kapadia
Journal:  J Mol Biol       Date:  2013-02-28       Impact factor: 5.469

9.  Hepatitis C virus epitope-specific neutralizing antibodies in Igs prepared from human plasma.

Authors:  Pei Zhang; Charles G Wu; Kathleen Mihalik; Maria Luisa Virata; Mei-Ying W Yu; Harvey J Alter; Stephen M Feinstone
Journal:  Proc Natl Acad Sci U S A       Date:  2007-05-09       Impact factor: 11.205

Review 10.  Mouse Systems to Model Hepatitis C Virus Treatment and Associated Resistance.

Authors:  Ahmed Atef Mesalam; Koen Vercauteren; Philip Meuleman
Journal:  Viruses       Date:  2016-06-22       Impact factor: 5.048

View more
  2 in total

1.  Functional Study of the C-Terminal Part of the Hepatitis C Virus E1 Ectodomain.

Authors:  Rehab I Moustafa; Juliano G Haddad; Lydia Linna; Xavier Hanoulle; Véronique Descamps; Ahmed Atef Mesalam; Thomas F Baumert; Gilles Duverlie; Philip Meuleman; Jean Dubuisson; Muriel Lavie
Journal:  J Virol       Date:  2018-09-26       Impact factor: 5.103

Review 2.  Role of Hepatitis C Virus Envelope Glycoprotein E1 in Virus Entry and Assembly.

Authors:  Yimin Tong; Dimitri Lavillette; Qingchao Li; Jin Zhong
Journal:  Front Immunol       Date:  2018-06-19       Impact factor: 7.561

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.